TABLE 1.
Survival and other clinical outcomes from start of first‐line systemic anticancer therapy
| Disease type | All patients | Locally advanced, unresectable | Metastatic |
|---|---|---|---|
| Median months (95% CI) | |||
| Synovial sarcoma | N = 249 | N = 37 | N = 212 |
| Overall survival | 24.7 (20.9, 29.4) | 33.8 (21.3, 49.1) | 23.4 (19.9, 28.0) |
| Progression‐free survival | 7.5 (6.4, 8.4) | 8.6 (6.4, 12.4) | 7.5 (5.7, 8.3) |
| Time to next treatment | 9.2 (7.9, 10.2) | 10.1 (6.9, 22.0) | 9.2 (7.9, 10.2) |
| Time to distant metastasis | 21.8 (14.6, 32.6) | 14.6 (10.3, 29.3) | 27.1 (17.3, NR) |
| Myxoid/round cell liposarcoma | N = 101 | N = 9 | N = 92 |
| Overall survival | 29.9 (27, 44.6) | NR (4.6, NR) | 29.2 (26.2, 35.1) |
| Progression‐free survival | 8.9 (4.5, 12.0) | 12.5 (1.4, 17.0) | 8.0 (4.0, 11.5) |
| Time to next treatment | 12.2 (7.3, 15.2) | 27.1 (1.4, 70.8) | 11.0 (6.4, 14.5) |
| Time to distant metastasis | 17.0 (12.5, 52.4) | 17.0 (6.9, NR) | 17.5 (12.0, 52.4) |
Abbreviations: CI, confidence interval; NR, not reached.